NCT00748852View on ClinicalTrials.gov

Safety Study of JTT-302 in Subjects With Low HDL-C Levels

PHASE2CompletedINTERVENTIONAL

Enrollment

103

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions

Dyslipidemia

Interventions

DRUG

JTT-302

JTT-302, 100 mg tablets, 400 mg dose, oral, 30 minutes after the start of the morning meal

Trial Locations (1)

Unknown

Santa Ana

Sponsors

Lead Sponsor

Akros Pharma Inc.

All Listed Sponsors

lead

Akros Pharma Inc.

INDUSTRY

NCT00748852 - Safety Study of JTT-302 in Subjects With Low HDL-C Levels | Biotech Hunter | Biotech Hunter